XL228, with the CAS number 898280-07-4, is a small molecule that functions primarily as a kinase inhibitor. It has been investigated for its potential therapeutic applications, particularly in the treatment of various cancers. The compound selectively targets specific kinases involved in cellular signaling pathways that regulate cell growth and survival, making it a candidate for cancer therapy. XL228 exhibits a unique chemical structure that contributes to its biological activity, although detailed structural information is typically proprietary. In preclinical studies, it has shown promise in inhibiting tumor growth and overcoming resistance to other therapies. As with many investigational drugs, the safety and efficacy of XL228 are evaluated through clinical trials, and its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are critical for understanding its potential as a therapeutic agent. Further research is necessary to fully elucidate its mechanism of action and to establish optimal dosing regimens for clinical use.

XL228

Find at CymitQuimica all products linked to CAS 898280-07-4. Enter now to get more information

XL228 is an advanced bioactive compound, which is a synthetic molecule designed to target specific cellular pathways by modulating gene expression. It is derived from a chemically engineered process, ensuring high specificity and purity. By selectively inhibiting or activating key signaling cascades within target cells, XL228 can effectively alter cellular function at a molecular level.

The primary applications of XL228 include research on cellular mechanisms, where it serves as a valuable tool for dissecting pathways involved in growth, differentiation, or apoptosis. Its precise mode of action also makes it suitable for use in the development of therapeutic strategies against various disorders, including cancer and autoimmune diseases. Furthermore, its role in modulating kinase activity positions it as an integral part of experimental protocols that require precise intervention in signal transduction studies.

XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).

CAS 898280-07-4: XL228

XL228

Ref: 3D-YKB28007

XL228

Ref: TM-T17267

XL 228

Ref: IN-DA00GU7G

XL228

Ref: 54-BUP05213